LGND - Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
2024-04-29 22:01:18 ET
Summary
- Royalty Aggregators like Royalty Pharma, Ligand, and XOMA are gaining popularity in the biotech industry.
- These companies buy up royalty rights to pharmaceutical products, providing upfront cash to biotech companies.
- This allows biotech companies to access immediate funds for research and development, while the aggregators earn a return on their investment.
This is my sixth article on royalty aggregator Ligand Pharmaceuticals ( LGND ). My most recent previous Ligand article was 06/2023's "Ligand Pharmaceuticals: The New Ligand (" New Ligand "). In it I rated Ligand as a "Buy". At the time it was selling for $76.42....
Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio